Agitation is one of the most common symptoms of Alzheimer’s disease, leading patients to become restless or even verbally and physically aggressive. The FDA has approved the first drug to treat these behavioral symptoms.
The Thursday approval of the drug, brexpiprazole (brand name Rexulti),…
Source: medcitynews.com – Read more
FDA Approves First Drug for Treating Agitation in Alzheimer’s Patients
Must Read
Why did SentinelOne shares plummet by 35% in a single day?
The highest-valued cybersecurity IPO in history was that of Israel-founded company SentinelOne, which has been managed since its inception by Tomer Weingarten. The offering,...
